tradingkey.logo
tradingkey.logo
Search

ProKidney jumps on positive mid-stage data for kidney disease drug

ReutersJul 8, 2025 12:12 PM
facebooktwitterlinkedin
View all comments0

Shares of ProKidney PROK.O rise 62.4% to $1.25 cents premarket

Co says its drug, rilparencel, showed improvement in kidney function decline in patients with chronic kidney disease and diabetes during mid-stage trial

PROK has upcoming meeting with Food and Drug Administration to confirm approach of drug's planned late-stage trial

Up to last close, stock down 64% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI